FDA IID release Inactive Ingredients Database Download File

Browse every parsed inactive-ingredient row and every release-scoped FDA change-log record from this recovered source artifact.

FDA source artifact

Download archived FDA source ZIP

Edition: Inactive Ingredients Database Download File
Edition date: 2026-10-15
Snapshot ID: d48ce29c5bf7ecd3246fa34d33df379898dbd110ec910e6875790875aaa5cacf
Source member: IIR_OCOMM.xls
Source bytes: 675,976
Source SHA-256: d387d58ad653eedb79d5a5291ef4d1fe5f2486585c9a3b9f4c49882f00761309
Archived object key: import-staging/iid/raw/d387d58ad653eedb79d5a5291ef4d1fe5f2486585c9a3b9f4c49882f00761309/iid-edition-001.zip
Parser version: iid-2026-10-23-v2
Imported: 2026-10-23 00:09:42

IID snapshot rows#

These are the actual parsed IID rows from this one FDA source artifact. Raw FDA values are preserved and HTML-escaped.

Source row, Ingredient, UNII table
Source row	Ingredient	UNII	CAS	Dosage form	Route	Potency	Maximum daily exposure	Row SHA-256	Raw source values
2	.ALPHA.-TERPINEOL	21334LVV8W	98555	LOTION	TOPICAL	11 %w/w		`fa664dc1c246…`	Raw FDA values `[".ALPHA.-TERPINEOL", "TOPICAL", "LOTION", "98555", "21334LVV8W", "11", "%w/w", "", "", ""]`
3	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	FILM, SOLUBLE	BUCCAL	0.07 mg		`b08cdf32f3d8…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "BUCCAL", "FILM, SOLUBLE", "1406184", "H4N855PNZ1", "0.07", "mg", "", "", ""]`
4	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	INJECTION, POWDER, FOR SUSPENSION	INTRAVENOUS	0.64 mg		`5a1aed259760…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "INTRAVENOUS", "INJECTION, POWDER, FOR SUSPENSION", "1406184", "H4N855PNZ1", "0.64", "mg", "", "", ""]`
5	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	CAPSULE	ORAL		16 mg	`e3eedbd0a901…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "CAPSULE", "1406184", "H4N855PNZ1", "", "", "16", "mg", ""]`
6	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	SOLUTION	ORAL	1.05 mg/1ml		`9d7a0bcf58dd…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "SOLUTION", "1406184", "H4N855PNZ1", "1.05", "mg/1ml", "", "", ""]`
7	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	TABLET	ORAL		2 mg	`d523db6eeb2d…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET", "1406184", "H4N855PNZ1", "", "", "2", "mg", ""]`
8	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	TABLET, CHEWABLE	ORAL	0.1 mg		`1bc43083e964…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET, CHEWABLE", "1406184", "H4N855PNZ1", "0.1", "mg", "", "", ""]`
9	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	TABLET, EXTENDED RELEASE	ORAL		4 mg	`e45836b40460…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET, EXTENDED RELEASE", "1406184", "H4N855PNZ1", "", "", "4", "mg", ""]`
10	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	TABLET, FILM COATED	ORAL		246 mg	`3fa6f42c36ac…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "ORAL", "TABLET, FILM COATED", "1406184", "H4N855PNZ1", "", "", "246", "mg", ""]`
11	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	OINTMENT	TOPICAL	NA		`0bb3325402a3…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "TOPICAL", "OINTMENT", "1406184", "H4N855PNZ1", "", "NA", "", "", ""]`
12	.ALPHA.-TOCOPHEROL	H4N855PNZ1	1406184	SYSTEM	TOPICAL	0.1 mg		`021f518512a2…`	Raw FDA values `[".ALPHA.-TOCOPHEROL", "TOPICAL", "SYSTEM", "1406184", "H4N855PNZ1", "0.1", "mg", "", "", ""]`
13	.ALPHA.-TOCOPHEROL ACETATE	9E8X80D2L0	7695912	FILM	BUCCAL	0.09 mg		`59923c224546…`	Raw FDA values `[".ALPHA.-TOCOPHEROL ACETATE", "BUCCAL", "FILM", "7695912", "9E8X80D2L0", "0.09", "mg", "", "", ""]`
14	.ALPHA.-TOCOPHEROL ACETATE	9E8X80D2L0	7695912	CAPSULE	ORAL	2 mg		`50fc4092e724…`	Raw FDA values `[".ALPHA.-TOCOPHEROL ACETATE", "ORAL", "CAPSULE", "7695912", "9E8X80D2L0", "2", "mg", "", "", ""]`
15	.ALPHA.-TOCOPHEROL ACETATE	9E8X80D2L0	7695912	TABLET	ORAL	0.5 mg		`68bb5b6eadf2…`	Raw FDA values `[".ALPHA.-TOCOPHEROL ACETATE", "ORAL", "TABLET", "7695912", "9E8X80D2L0", "0.5", "mg", "", "", ""]`
16	.ALPHA.-TOCOPHEROL ACETATE, DL-	WR1WPI7EW8	7695912	AEROSOL, FOAM	TOPICAL	NA		`0f77333df5ee…`	Raw FDA values `[".ALPHA.-TOCOPHEROL ACETATE, DL-", "TOPICAL", "AEROSOL, FOAM", "7695912", "WR1WPI7EW8", "", "NA", "", "", ""]`
17	.ALPHA.-TOCOPHEROL ACETATE, DL-	WR1WPI7EW8	7695912	OINTMENT	TOPICAL	NA		`89d52c081a3e…`	Raw FDA values `[".ALPHA.-TOCOPHEROL ACETATE, DL-", "TOPICAL", "OINTMENT", "7695912", "WR1WPI7EW8", "", "NA", "", "", ""]`
18	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	INJECTION, EMULSION	INTRAVENOUS		178 mg	`a0c9bf45e36b…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "INTRAVENOUS", "INJECTION, EMULSION", "10191410", "7QWA1RIO01", "", "", "178", "mg", ""]`
19	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	SOLUTION, CONCENTRATE	INTRAVENOUS	0.08 %w/v		`7b317556e44c…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "INTRAVENOUS", "SOLUTION, CONCENTRATE", "10191410", "7QWA1RIO01", "0.08", "%w/v", "", "", ""]`
20	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	CAPSULE	ORAL		90 mg	`5df379a1d617…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "ORAL", "CAPSULE", "10191410", "7QWA1RIO01", "", "", "90", "mg", ""]`
21	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	POWDER, FOR SUSPENSION	ORAL	NA		`54ff22a338fe…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "ORAL", "POWDER, FOR SUSPENSION", "10191410", "7QWA1RIO01", "", "NA", "", "", ""]`
22	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	SOLUTION	ORAL		4 mg	`9aa9fd1d1448…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "ORAL", "SOLUTION", "10191410", "7QWA1RIO01", "", "", "4", "mg", ""]`
23	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	SUSPENSION	ORAL	0.01 mg/1ml		`e6f9f534dd04…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "ORAL", "SUSPENSION", "10191410", "7QWA1RIO01", "0.01", "mg/1ml", "", "", ""]`
24	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	TABLET	ORAL	0.12 mg		`7e051162cc1d…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "ORAL", "TABLET", "10191410", "7QWA1RIO01", "0.12", "mg", "", "", ""]`
25	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	TABLET, CHEWABLE	ORAL	0.02 mg		`3da07e9b4d9c…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "ORAL", "TABLET, CHEWABLE", "10191410", "7QWA1RIO01", "0.02", "mg", "", "", ""]`
26	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	AEROSOL, FOAM	TOPICAL	0.02 mg		`f636b7291e77…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "TOPICAL", "AEROSOL, FOAM", "10191410", "7QWA1RIO01", "0.02", "mg", "", "", ""]`
27	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	OINTMENT	TOPICAL	NA		`ab9bbeb5ea83…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "TOPICAL", "OINTMENT", "10191410", "7QWA1RIO01", "", "NA", "", "", ""]`
28	.ALPHA.-TOCOPHEROL, DL-	7QWA1RIO01	10191410	SYSTEM	TRANSDERMAL	0.14 mg		`706203577d9b…`	Raw FDA values `[".ALPHA.-TOCOPHEROL, DL-", "TRANSDERMAL", "SYSTEM", "10191410", "7QWA1RIO01", "0.14", "mg", "", "", ""]`
29	1-(PHENYLAZO)-2-NAPHTHYLAMINE	3VSI4D701X	85847	CAPSULE	ORAL	0.13 mg		`3549b9b9d59d…`	Raw FDA values `["1-(PHENYLAZO)-2-NAPHTHYLAMINE", "ORAL", "CAPSULE", "85847", "3VSI4D701X", "0.13", "mg", "", "", ""]`
30	1-(PHENYLAZO)-2-NAPHTHYLAMINE	3VSI4D701X	85847	TABLET	ORAL	0.2 mg		`54d40f7fd97d…`	Raw FDA values `["1-(PHENYLAZO)-2-NAPHTHYLAMINE", "ORAL", "TABLET", "85847", "3VSI4D701X", "0.2", "mg", "", "", ""]`
31	1,2,6-HEXANETRIOL	W45XXM0XWE	106694	CREAM	TOPICAL		43 mg	`3ae42a86b734…`	Raw FDA values `["1,2,6-HEXANETRIOL", "TOPICAL", "CREAM", "106694", "W45XXM0XWE", "", "", "43", "mg", ""]`
32	1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE	H026DM5V6U	4235954	INJECTION, SUSPENSION, LIPOSOMAL	EPIDURAL		8 mg	`9a2a18969a9e…`	Raw FDA values `["1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE", "EPIDURAL", "INJECTION, SUSPENSION, LIPOSOMAL", "4235954", "H026DM5V6U", "", "", "8", "mg", ""]`
33	1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE	043IPI2M0K	816944	INJECTABLE, LIPOSOMAL	INTRAVENOUS	2.8 %w/v		`bb111b333045…`	Raw FDA values `["1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE", "INTRAVENOUS", "INJECTABLE, LIPOSOMAL", "816944", "043IPI2M0K", "2.8", "%w/v", "", "", ""]`
34	1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE	043IPI2M0K	816944	INJECTION	INTRAVENOUS		68 mg	`44135dbd262c…`	Raw FDA values `["1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE", "INTRAVENOUS", "INJECTION", "816944", "043IPI2M0K", "", "", "68", "mg", ""]`
35	1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE	043IPI2M0K	816944	INJECTION, POWDER, FOR SUSPENSION	INTRAVENOUS	NA		`326f641a1ff5…`	Raw FDA values `["1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE", "INTRAVENOUS", "INJECTION, POWDER, FOR SUSPENSION", "816944", "043IPI2M0K", "", "NA", "", "", ""]`
36	1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE	043IPI2M0K	816944	CAPSULE	RESPIRATORY (INHALATION)		51 mg	`b81dadd26712…`	Raw FDA values `["1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE", "RESPIRATORY (INHALATION)", "CAPSULE", "816944", "043IPI2M0K", "", "", "51", "mg", ""]`
37	1,4-SORBITAN	AV0YTZ4E6J	27299123	CAPSULE	ORAL		242 mg	`4e427c1f66af…`	Raw FDA values `["1,4-SORBITAN", "ORAL", "CAPSULE", "27299123", "AV0YTZ4E6J", "", "", "242", "mg", ""]`
38	2-(4-STYRYL-3-SULFOPHENOL)-6-METHOXYBENZOTRIAZOLE	0MMD46SPU6	1333659	SOAP	TOPICAL	0.75 %w/w		`fda01d84719b…`	Raw FDA values `["2-(4-STYRYL-3-SULFOPHENOL)-6-METHOXYBENZOTRIAZOLE", "TOPICAL", "SOAP", "1333659", "0MMD46SPU6", "0.75", "%w/w", "", "", ""]`
39	2-ETHYLHEXYL ACRYLATE-GLYCIDYL METHACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 387-2287)	NA		FILM	TRANSDERMAL	NA		`43cca3d1ca4f…`	Raw FDA values `["2-ETHYLHEXYL ACRYLATE-GLYCIDYL METHACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 387-2287)", "TRANSDERMAL", "FILM", "", "NA", "", "NA", "", "", ""]`
40	2-ETHYLHEXYL ACRYLATE-GLYCIDYL METHACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 387-2287)	NA		FILM, EXTENDED RELEASE	TRANSDERMAL	NA		`af8b283dbd61…`	Raw FDA values `["2-ETHYLHEXYL ACRYLATE-GLYCIDYL METHACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 387-2287)", "TRANSDERMAL", "FILM, EXTENDED RELEASE", "", "NA", "", "NA", "", "", ""]`
41	2-ETHYLHEXYL ACRYLATE-GLYCIDYL METHACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 387-2287)	NA		SYSTEM	TRANSDERMAL	NA		`d658bbe67e7c…`	Raw FDA values `["2-ETHYLHEXYL ACRYLATE-GLYCIDYL METHACRYLATE-2-HYDROXYETHYL ACRYLATE-VINYL ACETATE COPOLYMER (FOR DURO-TAK 387-2287)", "TRANSDERMAL", "SYSTEM", "", "NA", "", "NA", "", "", ""]`
42	2-ETHYLHEXYL ACRYLATE-VINYL ACETATE-ALUMINUM ACRYLATE COPOLYMER (FOR DURO-TAK 87-2194)	NA		FILM, EXTENDED RELEASE	TRANSDERMAL	NA		`b9001451f023…`	Raw FDA values `["2-ETHYLHEXYL ACRYLATE-VINYL ACETATE-ALUMINUM ACRYLATE COPOLYMER (FOR DURO-TAK 87-2194)", "TRANSDERMAL", "FILM, EXTENDED RELEASE", "", "NA", "", "NA", "", "", ""]`
43	2-NAPHTHOL	P2Z71CIK5H	135193	CAPSULE	ORAL	0.3 mg		`2db70d15216f…`	Raw FDA values `["2-NAPHTHOL", "ORAL", "CAPSULE", "135193", "P2Z71CIK5H", "0.3", "mg", "", "", ""]`
44	ACACIA	5C5403N26O	9000015	GUM, CHEWING	BUCCAL		280 mg	`98b4dfc3dd37…`	Raw FDA values `["ACACIA", "BUCCAL", "GUM, CHEWING", "9000015", "5C5403N26O", "", "", "280", "mg", ""]`
45	ACACIA	5C5403N26O	9000015	TABLET	BUCCAL	9.1 mg		`c7d8b4d859c3…`	Raw FDA values `["ACACIA", "BUCCAL", "TABLET", "9000015", "5C5403N26O", "9.1", "mg", "", "", ""]`
46	ACACIA	5C5403N26O	9000015	SUSPENSION	INTRAMUSCULAR	1 mg		`fe76cb66a6b6…`	Raw FDA values `["ACACIA", "INTRAMUSCULAR", "SUSPENSION", "9000015", "5C5403N26O", "1", "mg", "", "", ""]`
47	ACACIA	5C5403N26O	9000015	CAPSULE	ORAL		20 mg	`385674da6b7e…`	Raw FDA values `["ACACIA", "ORAL", "CAPSULE", "9000015", "5C5403N26O", "", "", "20", "mg", ""]`
48	ACACIA	5C5403N26O	9000015	CAPSULE, EXTENDED RELEASE	ORAL		64 mg	`f14c88ea110c…`	Raw FDA values `["ACACIA", "ORAL", "CAPSULE, EXTENDED RELEASE", "9000015", "5C5403N26O", "", "", "64", "mg", ""]`
49	ACACIA	5C5403N26O	9000015	LOZENGE	ORAL		108 mg	`64df444052f2…`	Raw FDA values `["ACACIA", "ORAL", "LOZENGE", "9000015", "5C5403N26O", "", "", "108", "mg", ""]`
50	ACACIA	5C5403N26O	9000015	POWDER	ORAL	800 mg		`c0b4001c2f62…`	Raw FDA values `["ACACIA", "ORAL", "POWDER", "9000015", "5C5403N26O", "800", "mg", "", "", ""]`
51	ACACIA	5C5403N26O	9000015	POWDER, FOR SOLUTION	ORAL	NA		`dbfc16796408…`	Raw FDA values `["ACACIA", "ORAL", "POWDER, FOR SOLUTION", "9000015", "5C5403N26O", "", "NA", "", "", ""]`

IID release change log#

Release-scoped records: FDA change-log rows are published exactly as recovered for this release. The source does not provide a safe ingredient-row key, so these records are not attributed to any ingredient above.

Source member, Source row, Change ID table
Source member	Source row	Change ID	Snapshot label	Status	Raw FDA JSON
Change_Log_Data.csv	2	39	Q3 2026	C	`{"Status": "C", "Change ID": "39", "Dosage Form": "TABLET, DELAYED RELEASE", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "2-AMINOETHANOL", "Maximum Daily Exposure": "1", "Route Of Administration": "ORAL", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	3	39	Q4 2026	C	`{"Status": "C", "Change ID": "39", "Dosage Form": "TABLET, DELAYED RELEASE", "Snapshot Date": "Q4 2026", "Inactive Ingredient": "ETHANOLAMINE", "Maximum Daily Exposure": "1", "Route Of Administration": "ORAL", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	4	1468	Q3 2026	C	`{"Status": "C", "Change ID": "1468", "Dosage Form": "TABLET", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "CROSCARMELLOSE", "Maximum Daily Exposure": "80", "Route Of Administration": "ORAL", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	5	1468	Q4 2026	C	`{"Status": "C", "Change ID": "1468", "Dosage Form": "TABLET", "Snapshot Date": "Q4 2026", "Inactive Ingredient": "CROSCARMELLOSE", "Maximum Daily Exposure": "44", "Route Of Administration": "ORAL", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	6	2420	Q3 2026	C	`{"Status": "C", "Change ID": "2420", "Dosage Form": "TABLET", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "FD&C RED NO. 40", "Maximum Daily Exposure": "7", "Route Of Administration": "ORAL", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	7	2420	Q4 2026	C	`{"Status": "C", "Change ID": "2420", "Dosage Form": "TABLET", "Snapshot Date": "Q4 2026", "Inactive Ingredient": "FD&C RED NO. 40", "Maximum Daily Exposure": "4", "Route Of Administration": "ORAL", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	8	2630	Q3 2026	C	`{"Status": "C", "Change ID": "2630", "Dosage Form": "SOLUTION", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "FLAVOR CHERRY 842", "Maximum Daily Exposure": "832", "Route Of Administration": "ORAL", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	9	2630	Q4 2026	C	`{"Status": "C", "Change ID": "2630", "Dosage Form": "SOLUTION", "Snapshot Date": "Q4 2026", "Inactive Ingredient": "FLAVOR CHERRY 842", "Maximum Daily Exposure": "356", "Route Of Administration": "ORAL", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	10	3185	Q3 2026	C	`{"Status": "C", "Change ID": "3185", "Dosage Form": "INJECTION, SUSPENSION", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "HYALURONATE SODIUM", "Maximum Daily Exposure": "23", "Route Of Administration": "INTRA-ARTICULAR", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	11	3185	Q4 2026	C	`{"Status": "C", "Change ID": "3185", "Dosage Form": "INJECTION, SUSPENSION", "Snapshot Date": "Q4 2026", "Inactive Ingredient": "SODIUM HYALURONATE", "Maximum Daily Exposure": "23", "Route Of Administration": "INTRA-ARTICULAR", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	12	3186	Q3 2026	C	`{"Status": "C", "Change ID": "3186", "Dosage Form": "INJECTION, SUSPENSION", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "HYALURONATE SODIUM", "Maximum Daily Exposure": "23", "Route Of Administration": "INTRAMUSCULAR", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	13	3186	Q4 2026	C	`{"Status": "C", "Change ID": "3186", "Dosage Form": "INJECTION, SUSPENSION", "Snapshot Date": "Q4 2026", "Inactive Ingredient": "SODIUM HYALURONATE", "Maximum Daily Exposure": "23", "Route Of Administration": "INTRAMUSCULAR", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	14	3187	Q3 2026	C	`{"Status": "C", "Change ID": "3187", "Dosage Form": "INJECTION, SUSPENSION", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "HYALURONATE SODIUM", "Maximum Daily Exposure": "23", "Route Of Administration": "INTRAVITREAL", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	15	3187	Q4 2026	C	`{"Status": "C", "Change ID": "3187", "Dosage Form": "INJECTION, SUSPENSION", "Snapshot Date": "Q4 2026", "Inactive Ingredient": "SODIUM HYALURONATE", "Maximum Daily Exposure": "23", "Route Of Administration": "INTRAVITREAL", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	16	3188	Q3 2026	C	`{"Status": "C", "Change ID": "3188", "Dosage Form": "GEL", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "HYALURONATE SODIUM", "Maximum Daily Exposure": "463", "Route Of Administration": "TOPICAL", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	17	3188	Q4 2026	C	`{"Status": "C", "Change ID": "3188", "Dosage Form": "GEL", "Snapshot Date": "Q4 2026", "Inactive Ingredient": "SODIUM HYALURONATE", "Maximum Daily Exposure": "463", "Route Of Administration": "TOPICAL", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	18	3189	Q3 2026	C	`{"Status": "C", "Change ID": "3189", "Dosage Form": "LOTION", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "HYALURONATE SODIUM", "Maximum Daily Exposure": "", "Route Of Administration": "TOPICAL", "Maximum Daily Exposure UOM": "", "Maximum Potency per Unit Dose": "0.01 %w/w"}`
Change_Log_Data.csv	19	3189	Q4 2026	C	`{"Status": "C", "Change ID": "3189", "Dosage Form": "LOTION", "Snapshot Date": "Q4 2026", "Inactive Ingredient": "SODIUM HYALURONATE", "Maximum Daily Exposure": "", "Route Of Administration": "TOPICAL", "Maximum Daily Exposure UOM": "", "Maximum Potency per Unit Dose": "0.01 %w/w"}`
Change_Log_Data.csv	20	6109	Q3 2026	C	`{"Status": "C", "Change ID": "6109", "Dosage Form": "INJECTION, POWDER, FOR SUSPENSION", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "POLYLACTIDE (14000 MW)", "Maximum Daily Exposure": "188", "Route Of Administration": "INTRAMUSCULAR", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	21	6109	Q4 2026	C	`{"Status": "C", "Change ID": "6109", "Dosage Form": "INJECTION, POWDER, FOR SUSPENSION", "Snapshot Date": "Q4 2026", "Inactive Ingredient": "DL-LACTIDE HOMOPOLYMER 14000 ACID", "Maximum Daily Exposure": "188", "Route Of Administration": "INTRAMUSCULAR", "Maximum Daily Exposure UOM": "mg", "Maximum Potency per Unit Dose": ""}`
Change_Log_Data.csv	22	265	Q3 2026	D	`{"Status": "D", "Change ID": "265", "Dosage Form": "TROCHE", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "AMARANTH", "Maximum Daily Exposure": "", "Route Of Administration": "BUCCAL", "Maximum Daily Exposure UOM": "", "Maximum Potency per Unit Dose": "0.05 mg"}`
Change_Log_Data.csv	23	266	Q3 2026	D	`{"Status": "D", "Change ID": "266", "Dosage Form": "CAPSULE", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "AMARANTH", "Maximum Daily Exposure": "", "Route Of Administration": "ORAL", "Maximum Daily Exposure UOM": "", "Maximum Potency per Unit Dose": "1.08 mg"}`
Change_Log_Data.csv	24	267	Q3 2026	D	`{"Status": "D", "Change ID": "267", "Dosage Form": "CAPSULE, EXTENDED RELEASE", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "AMARANTH", "Maximum Daily Exposure": "", "Route Of Administration": "ORAL", "Maximum Daily Exposure UOM": "", "Maximum Potency per Unit Dose": "0.18 mg"}`
Change_Log_Data.csv	25	268	Q3 2026	D	`{"Status": "D", "Change ID": "268", "Dosage Form": "ELIXIR", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "AMARANTH", "Maximum Daily Exposure": "", "Route Of Administration": "ORAL", "Maximum Daily Exposure UOM": "", "Maximum Potency per Unit Dose": "1.88 mg"}`
Change_Log_Data.csv	26	269	Q3 2026	D	`{"Status": "D", "Change ID": "269", "Dosage Form": "LIQUID", "Snapshot Date": "Q3 2026", "Inactive Ingredient": "AMARANTH", "Maximum Daily Exposure": "", "Route Of Administration": "ORAL", "Maximum Daily Exposure UOM": "", "Maximum Potency per Unit Dose": "NA"}`